Neurogene Introduces Breakthrough NGN-401 Gene Therapy for the Treatment of Rett Syndrome
Neurogene has introduced NGN-401 for the treatment of patients with Rett syndrome, a rare neurological disorder characterised by severe developmental and functional impairments.
NGN-401 is an investigational gene therapy designed as a one-time treatment to deliver the full-length human MECP2 gene. It uses a proprietary transgene regulation technology to control gene expression and is administered directly into the brain to achieve broad distribution across the central nervous system.
The Breakthrough Therapy Designation from the U.S. Food and Drug Administration is supported by interim clinical data from an ongoing Phase 1/2 trial. The results demonstrated meaningful and sustained improvements across multiple functional areas, along with continued skill development over time. NGN-401 is currently being further evaluated in the Embolden™ registrational clinical trial, with dosing expected to be completed in 2026.
NGN-401 has also received several additional regulatory designations, including Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug and Rare Paediatric Disease designations from the U.S. Food and Drug Administration. It has also been included in the START Pilot Programme, which supports the development of treatments for rare diseases.
Rett syndrome is a rare genetic neurological condition that primarily affects girls and leads to a loss of motor and communication skills, along with cognitive impairment and other complications. The condition has limited treatment options and represents a significant unmet medical need.
NGN-401 is currently in late-stage clinical development as part of Neurogene’s broader programme focused on developing genetic medicines for neurological disorders.
